ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial

References

• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet365, 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet367, 1747–1757 (2006).
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N. Engl. J. Med.334, 1649–1654 (1996).
   PubMed Web of Science ®Google Scholar
• Messeli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch. Intern. Med.156, 1957–1965 (1996).
   PubMedGoogle Scholar
• Staessen JA, Fagard T, Thijs L et al.; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet350, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Demers C, McMurray JJ, Swedberg K et al.; CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA294, 1794–1798 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Davis BR, Furberg CD, Wright JT et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid lowering treatment to prevent heart attack Trial (ALLHAT). JAMA283, 1967–1975 (2000).
   PubMedGoogle Scholar
• Brown M, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet356, 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• WHO; International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens.21, 1983–1989 (2003).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Commitee on prevention, detection, evaluation, and treatment of high blood pressure (The JNC 7 Report). JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J.28, 1462–1536 (2007).
   PubMed Web of Science ®Google Scholar
• Fukui T, Rahman M, Hayashi K et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens. Res.26, 979–990 (2003).
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension51, 393–398 (2008).
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hypertension Guidelines Subcommittee for the management of hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens. Res.24, 613–634 (2001).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol.57, 450–458 (1986).
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med.115, 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Dahlöf B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation110, 1456–1462 (2004).
   PubMed Web of Science ®Google Scholar
• Mitsunami K, Inoue S, Maeda K et al. Three-month effects of candesartan cilexetil, an angiotensin II Type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc. Drugs Ther.12, 469–474 (1998).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Muiesan ML, Valagussa L et al.; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens.20, 2293–2300 (2002).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Mancia G et al. VALUE Trial Investigators. Effects of valsartan compared with amlodipine on preventing Type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens.24, 1405–1412 (2006).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. LIFE study group. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J. Hypertens.20, 1879–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369, 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation97, 48–54 (1998).
   PubMed Web of Science ®Google Scholar
• Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am. J. Hypertens.15, 1021–1028 (2002).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA292, 2350–2356 (2004).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension43, 963–969 (2004).
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population. Hypertension50, 467–473 (2007).
   PubMed Web of Science ®Google Scholar
• Held C, Gerstein HC, Yusuf S et al.; ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation115, 1371–1375 (2007).
   PubMed Web of Science ®Google Scholar